Eli Lilly To Acquire Kelonia In $7 Billion Deal

Eli Lilly has agreed to acquire biotech firm Kelonia Therapeutics in a deal valued at up to $7 billion, the company announced Monday. Lilly will pay $3.25 billion upfront, with additional payments tied to clinical and commercial milestones, according to the company.

Eli Lilly has agreed to buy Kelonia Therapeutics for as much as $7 billion, gaining access to a potential cutting-edge treatment for blood cancer https://t.co/TDBcbgHIkk

— Bloomberg (@business) April 20, 2026

The deal is expected to close in the second half of 2026. Kelonia is developing in vivo CAR-T therapy, a method that reprograms a patient’s T-cells inside the body to fight cancer. This approach aims to simplify existing ex vivo treatments, which require complex lab procedures.

Lilly executives said the therapy could expand access beyond specialized centers. The company is seeking to strengthen its position in cancer treatment, particularly in blood cancers.

The move follows rising competition in the CAR-T space, with major players investing heavily in next-generation therapies, the report said.

Also Read:

Why Did The U.S. Seize An Iran-Linked Ship

The U.S. military has seized an Iran-linked cargo vessel in the Arabian Sea, escalating tensions amid ongoing conflict and fragile peace talks, CNN reported. The ship, identified as the M/V Touska, was intercepted after allegedly defying a U.S. naval blockade on Iranian ports. According to U.S.

tippinsightsTIPP Staff